The U.S. Food and Drug Administration (FDA) has approved LISRAYA (brepocitinib) 30 mg tablets, developed by Priovant Therapeutics (a Roivant Sciences / Pfizer venture), for the treatment of adult dermatomyositis (DM) — a rare, systemic immune‑mediated disease affecting muscle, skin and potentially lung and cardiovascular systems. The FDA explicitly described LISRAYA as the first approved oral treatment option for adult dermatomyositis and the first targeted JAK/TYK2 small molecule approved in the indication. Notably, LISRAYA is not the first FDA‑approved DM therapy overall — Octagam 10% (IV immunoglobulin) was approved in 2021 — but its once‑daily oral, mechanism‑targeted profile marks a new treatment paradigm for the disease.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. FDA |
| Approval Type | NDA 220106; approval of first oral targeted therapy for adult DM |
| Product | LISRAYA (brepocitinib) 30 mg oral tablets, once daily, with or without food |
| Indication | Adult dermatomyositis (DM) |
| Approval Date | 27 August 2026 |
| Pivotal Evidence | Global Phase 3 VALOR trial (NCT05437263), 52 weeks double‑blind |
| Boxed Warning | Serious infections, death, malignancy, major adverse cardiovascular events (MACE), and thrombosis (JAK‑class warnings) |
Drug Profile & Mechanism of Action
- Molecule: Brepocitinib (development code PF‑06700841), marketed as the tosylate salt; each 30 mg tablet contains brepocitinib equivalent to 43.27 mg brepocitinib tosylate (pink, capsule‑shaped, immediate‑release film‑coated tablet).
- Target: Oral, relatively selective dual TYK2/JAK1 inhibitor — inhibits TYK2 and JAK1 more potently than JAK2, with higher selectivity over JAK3, suppressing multiple autoimmune‑relevant cytokine axes including Type I/II interferon, IL‑6 and IL‑12/IL‑23 signaling.
- Pharmacokinetics: Median Tmax ≈ 1 hour; absolute oral bioavailability ≈ 75%; terminal half‑life 5.4–12 hours; primarily metabolized via CYP1A1/CYP1A2 (minor CYP3A4). Approved for administration with or without food.
- Clinical Positioning: Improves dermatomyositis across multiple disease domains — muscle, skin, physical function and overall disease burden — while reducing systemic corticosteroid dependence, per company disclosures.
- Origin & Ownership: Licensed from Pfizer to Priovant Therapeutics (established with Roivant in 2021; Pfizer retained ~25% equity and ex‑U.S./Japan commercial rights) — a textbook biotech asset‑development path.
Clinical Evidence – Phase 3 VALOR Trial
The VALOR study randomized 241 adults with dermatomyositis 1:1:1 to brepocitinib 30 mg, brepocitinib 15 mg, or placebo once daily for 52 weeks double‑blind, on stable background therapy with protocol‑mandated corticosteroid tapering. The primary endpoint was Week 52 Total Improvement Score (TIS), a composite of six core measures (PhGA, PtGA, MMT‑8, EMGA, HAQ‑DI, muscle enzymes). All 9 key secondary endpoints were met, with treatment effects emerging as early as Week 4.
| Endpoint (Week 52 unless noted) | Brepocitinib 30 mg | Placebo | Relative Benefit |
|---|---|---|---|
| Mean TIS (NEJM) | 46.5 | 31.2 | Difference 15.3 (95% CI 6.7–24.0; P<0.001) |
| LS Mean TIS (FDA label) | 47.5 | 33.3 | Stratified‑adjusted difference |
| TIS ≥ 60 (Major Improvement) | 48% | 26% | +22 ppt |
| TIS moderate+ improvement with minimal/no steroid use | 55% | 30% | +25 ppt |
| Corticosteroid reduction to ≤2.5 mg/day (baseline ≥7.5 mg/day prednisone equivalent) | ≈62% | ≈38% | +24 ppt |
| Complete corticosteroid discontinuation | ≈45% | ≈29% | +16 ppt |
| CDASI‑A skin response (JAMA Dermatology) | 61.7% | 44.3% | +16.8 ppt |
| ≥2‑point itch improvement (moderate‑severe baseline) | 74.0% | 33.3% | +40.7 ppt |
| Skin clearance/almost clearance (moderate‑severe baseline) | 45.7% | 21.8% | +23.9 ppt |
Safety: Overall adverse‑event rates were similar across groups, but serious infections were markedly higher with brepocitinib 30 mg (~10% vs ~1% placebo; 9.9% vs 1.3% per JAMA Dermatology reanalysis**)**; no deaths occurred during the trial. The 15 mg dose did not achieve statistical superiority on the primary endpoint, underscoring the dose–efficacy–safety balance challenge for dual JAK1/TYK2 inhibition. The label mandates TB screening, baseline CBC, hepatic/renal assessment, vaccination updates, pregnancy verification, and advises against combination with other JAK/TYK2 inhibitors or biologic DMARDs.
Market Impact & Outlook
- Unmet Need in a Rare, Multi‑System Disease: Dermatomyositis causes symmetric proximal muscle weakness, characteristic rash, and potentially interstitial lung disease, dysphagia and cardiac involvement. Prior U.S. care relied on corticosteroids, immunosuppressants, antimalarials and IVIG; LISRAYA introduces a once‑daily oral, biology‑targeted option with a fundamentally different long‑term management logic.
- Steroid‑Sparing Value Proposition: The clinical narrative extends beyond score improvement to reducing long‑term systemic corticosteroid dependence — a core value driver for chronically immunosuppressed patients.
- One Molecule, Multiple Indications: Priovant is advancing brepocitinib into non‑infectious uveitis, cutaneous sarcoidosis and lichen planopilaris (Phase 3/registrational and Phase 2b/3), building a multi‑indication autoimmune franchise that lowers marginal development cost per indication.
- Lifecycle & Patent Protection: Priovant holds exclusive licenses to 6 patent families covering brepocitinib (≥202 granted patents, 53 pending applications; compound, crystal forms, topical formulations, manufacturing and methods of use). Earliest expiry ~2035, with potential patent term extension projected to protect the U.S. market into at least 2039.
- Real‑World Caveats: VALOR’s 241‑patient, predominantly female/white cohort, 20% baseline interstitial lung disease and ~65% with cardiovascular risk factors warrant careful post‑launch risk management; long‑term infection, malignancy, MACE and thrombosis safety, background‑DMARD tapering and real‑world persistence remain the key open questions.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization of LISRAYA (brepocitinib), ongoing and planned clinical development across additional autoimmune indications, patent exclusivity expectations, and market performance. Actual results may differ materially due to regulatory, competitive, safety, reimbursement and execution risks. LISRAYA carries an FDA Boxed Warning for serious infections, death, malignancy, MACE and thrombosis; risk–benefit should be individually assessed. Data referenced herein derive from FDA labeling, NEJM, JAMA Dermatology and company disclosures.-Fineline Info & Tech
